Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Share-based Compensation data on file, last reported at $10.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 51.92% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 89.55% decrease from a year earlier, with the FY2025 full-year figure at $80.2 million, down 28.9% from the prior year.
• Share-based Compensation for Q1 2026 stood at $10.5 million, down from $16.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for NTLA reached as high as $40.9 million in Q2 2024 and fell as low as -$1.8 million in Q4 2024.
• Historically, Share-based Compensation has averaged $23.1 million across 5 years, with a median of $23.1 million in 2022.
• Across the five-year window, Share-based Compensation surged 12460.22% in 2023 and slumped 105.24% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $279000.0 in 2022, then jumped by 12460.22% to $35.0 million in 2023, then slumped by 105.24% to -$1.8 million in 2024, then surged by 1012.21% to $16.7 million in 2025, then plunged by 37.27% to $10.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $10.5 million in Q1 2026, $16.7 million in Q4 2025, and $7.9 million in Q3 2025.